Sionna Therapeutics opened lower at $3.66, compared with its previous close of $3.70. In the last trading session, the stock traded between $3.39 and $3.66. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Sionna Therapeutics is now worth
$ 13.69
Resulting in a loss of
$ 86.31 (86.31%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
0%
Hold
100%
Sell
0%
Markets Today
Today's Change
$-0.28 (-7.49%)
Day High
$3.66
Day Low
$3.39
Day Open
$3.66
Prev Close
$3.70
Volume
3,11,362
1W Return
-8.01%
1M Return
-27.09%
3M Return
-32.91%
6M Return
-92.55%
1Y Return
-90.61%
Fundamentals
Market Cap ($ Mn)
155
PE Ratio
-
PB Ratio
0.99
PEG Ratio
-
ROE
-32.64%
ROCE
-29.06%
EPS (TTM)
-
Investment Returns
1 Week
-8.01%
1 Month
-27.09%
3 Months
-32.91%
6 Months
-92.55%
9 Months
-90.63%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Sionna Therapeutics Q3 Results: EPS miss of 16% as losses widen 56% YoY
Sionna Therapeutics reported a Q3 EPS of $(0.72), missing the $(0.62) estimate by 16.13%. Quarterly losses widened 56.52% YoY from $(0.46) in the prior year. The result reflects a significant deviation from analyst consensus expectations.
2 days ago
23Sep
Pomerantz investigates Sionna Therapeutics after 91% stock drop
Pomerantz LLP investigates Sionna Therapeutics for alleged securities fraud. Stock fell 91.18% to $4.50 following Phase 2a trial failure. PreciSION CF trial missed key endpoint for sweat chloride reduction. Legal action concerns practices of company officers and directors.
1mo ago
9Sep
Pomerantz LLP probes Sionna Therapeutics after 91% stock plunge
Pomerantz LLP joins two other firms in probing Sionna Therapeutics. Investigation follows 91.18% stock drop to $4.50 on August 10, 2026. Catalyst was failure of PreciSION CF Phase 2a trial for SION-719. Firm examines potential securities fraud by company and directors.
Glancy Prongay Wolke & Rotter LLP continues its securities fraud investigation into Sionna Therapeutics. The probe follows the August 10 failure of the SION-719 Phase 2a trial, causing a 91% stock drop. Sionna holds $268.3 million in cash, funding operations into 2028 despite the clinical setback. The firm identified SION-451 + SION-2222 as the preferred dual combination for future development. Investors with losses are urged to contact the firm for potential recovery claims.
